Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis

Michael Tachezy, Florian Gebauer, Monika Janot, Waldemar Uhl, Alessandro Zerbi, Marco Montorsi, Julie Perinel, Mustapha Adham, Christos Dervenis, Christos Agalianos, Giuseppe Malleo, Laura Maggino, Alexander Stein, Jakob R. Izbicki, Maximilian Bockhorn

Research output: Contribution to journalArticle

Abstract

Background: The prognosis of patients with liver metastasis is generally considered dismal, and combined resections of the primary tumor and metastasectomies are not recommended. In highly selected patients, however, resections are performed. The evidence for this indication is limited. The aim of the current study was to assess the operative and oncologic outcomes of patients with combined pancreatic and liver resections of synchronous liver metastases. Methods: In a retrospective analysis of 6 European pancreas centers, we identified 69 patients with pancreatic ductal adenocarcinoma and synchronous liver metastasis who underwent simultaneous pancreas and liver metastasis resections. Patients receiving exploration without tumor resection served as the control group. Results: Overall survival (OS) appeared to be prolonged in the group of resected patients (median 14 vs 8 months, P <.001). Subgroup analysis revealed that the survival benefit of the resected patients was driven by pancreatic ductal adenocarcinomas localized in the pancreatic head (median OS 13.6 vs 7 months, P <.001). Body/tail pancreatic ductal adenocarcinomas showed no benefit of resection (median OS 14 vs 15 months, P = .312). In the multivariate analysis, tumor resection was the only independent prognosticator for OS (hazard ratio 2.044, 95% confidence interval 1.342-3.114). Conclusion: The data of this retrospective and selective patient cohort suggested a clear survival benefit for patients undergoing synchronous pancreas and liver resections for pancreatic ductal adenocarcinoma, but due to the limitations of this retrospective study and very strong potential for selection bias, a strong conclusion for resection cannot be drawn. Prospective trials must validate these data and investigate the use of combined operative and systemic treatments in case of resectable metastatic pancreatic cancer. Is it time for a multicenter, prospective trial?

Original languageEnglish
JournalSurgery
DOIs
Publication statusAccepted/In press - 2016

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis'. Together they form a unique fingerprint.

  • Cite this

    Tachezy, M., Gebauer, F., Janot, M., Uhl, W., Zerbi, A., Montorsi, M., Perinel, J., Adham, M., Dervenis, C., Agalianos, C., Malleo, G., Maggino, L., Stein, A., Izbicki, J. R., & Bockhorn, M. (Accepted/In press). Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. https://doi.org/10.1016/j.surg.2016.02.019